Browse CRTAM

Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF07686 Immunoglobulin V-set domain
Function

Interaction with CADM1 promotes natural killer (NK) cell cytotoxicity and interferon-gamma (IFN-gamma) secretion by CD8+ cells in vitro as well as NK cell-mediated rejection of tumors expressing CADM3 in vivo.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001912 positive regulation of leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002347 response to tumor cell
GO:0002355 detection of tumor cell
GO:0002418 immune response to tumor cell
GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002423 natural killer cell mediated immune response to tumor cell
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002717 positive regulation of natural killer cell mediated immunity
GO:0002831 regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0002834 regulation of response to tumor cell
GO:0002836 positive regulation of response to tumor cell
GO:0002837 regulation of immune response to tumor cell
GO:0002839 positive regulation of immune response to tumor cell
GO:0002855 regulation of natural killer cell mediated immune response to tumor cell
GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell
GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0008037 cell recognition
GO:0009306 protein secretion
GO:0009595 detection of biotic stimulus
GO:0031341 regulation of cell killing
GO:0031343 positive regulation of cell killing
GO:0031349 positive regulation of defense response
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045954 positive regulation of natural killer cell mediated cytotoxicity
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005913 cell-cell adherens junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CRTAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CRTAM and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23530148Myeloid Leukemia; Burkitt Lymphoma; Colon CarcinomaPromote immunity (T cell function)CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CRTAM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CRTAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4330.285
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5110.451
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3840.524
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1590.0436
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.5850.138
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6380.558
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0040.111
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.8870.042
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0750.94
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5650.562
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1490.914
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1720.439
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CRTAM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRTAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRTAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRTAM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRTAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CRTAM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CRTAM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCRTAM
Namecytotoxic and regulatory T cell molecule
Aliases CD355; class I MHC restricted T cell associated molecule; class-I MHC-restricted T cell associated molecule; ......
Chromosomal Location11q24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CRTAM collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.